Add BrightSurf on Google Email

Mount Sinai scientists discover the cellular functions of a family of proteins integral to inflammatory diseases

Researchers revealed the biological mechanisms by which class II HDACs activate Th17 cell differentiation, leading to inflammation. A potent inhibitor, TMP269, was found to influence Th17 cell differentiation in a mouse model of ulcerative colitis, providing potential therapeutic approach for IBD treatment.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalProceedings of the National Academy of Sciences·DateApr 22, 2024

Dietary treatment more effective than medicines in IBS

A study published in The Lancet Gastroenterology & Hepatology found that dietary adjustments, such as a low FODMAP diet and low-carbohydrate diets, resulted in significantly reduced IBS symptoms for over seven out of ten patients. In contrast, medication-based treatment showed fewer symptom improvements.

SourceUniversity of Gothenburg·JournalThe Lancet Gastroenterology & Hepatology·TypeRandomized controlled/clinical trial·DateApr 18, 2024

Digital twin allows for tailored medication

A study published in Genome Medicine uses digital twins to computationally treat thousands of medications in individual patients with autoimmune diseases, finding promising results in mice and human tissue samples. The technology has the potential to revolutionize precision medicine by providing tailored medication for each patient.

SourceKarolinska Institutet·JournalGenome Medicine·DateMar 20, 2024

AGA announces 12-point plan to improve the care of all patients with inflammatory bowel disease (IBD)

The American Gastroenterological Association has proposed a 12-point plan to enhance IBD care in the US, focusing on insurer-mandated barriers such as prior authorization and step therapy. The plan aims to improve treatment access and quality for over three million Americans living with IBD.

SourceAmerican Gastroenterological Association·JournalClinical Gastroenterology and Hepatology·TypeSystematic review·DateFeb 28, 2024

AGA now recommends fecal microbiota transplant for the majority of recurrent C. diff patients

The American Gastroenterological Association recommends fecal microbiota transplant (FMT) as a safe and effective treatment for most patients with recurrent Clostridioides difficile infection. FMT offers hope to patients suffering from debilitating C. diff, enabling them to lead happy and healthy lives.

SourceAmerican Gastroenterological Association·JournalGastroenterology·TypeSystematic review·DateFeb 21, 2024

Autoimmune disease and pregnancy

A study published in Lancet eClinical Health found pregnancy outcomes for pregnant individuals with autoimmune disease vary greatly depending on the specific condition and individual factors. Research highlights the importance of considering comorbidities when discussing autoimmune disease and pregnancy.

SourceInstitute for Systems Biology·JournalEClinicalMedicine·TypeSystematic review·DateJan 31, 2024

Hypoxia visualized by endoscopic imaging as an objective indicator for assessing bowel urgency and ulcerative colitis disease activity

Researchers at University of Tsukuba discovered a correlation between hypoxia levels and clinical symptoms in UC patients. Lower oxygen saturation in the rectal mucosa was associated with greater severity of colitis, making this method a potential tool for objective measurement of disease activity.

SourceUniversity of Tsukuba·JournalGastrointestinal Endoscopy·DateJan 23, 2024

Cleveland Clinic and University of Western Ontario awarded $4.9 million from the Helmsley Charitable Trust to build Crohn’s disease and ileostomy research consortium

A new consortium, co-led by Florian Rieder, MD, and Vipul Jairath, MD, will create clinical care pathways toward drug development and improve disease management for patients with Crohn's disease and permanent ileostomy. The EndO-trial Consortium aims to develop effective drugs and measure treatment outcomes using patient-reported outco...

Miniature colons with immune components aid the study of intestinal diseases

Researchers at MUSC and Cincinnati Children's have developed a novel colon organoid model with naturally occurring immune cells. The model has the potential to improve treatment outcomes for colon-related diseases such as cancer and IBD by providing a more complete human organoid system that can be used to model inflammation in the colon.

SourceMedical University of South Carolina·JournalCell Stem Cell·TypeExperimental study·DateNov 20, 2023

Risk of serious infection even in low-active IBD

Research at the University of Gothenburg found that even low-active IBD patients have a higher risk of serious infections due to microscopic intestinal inflammation. Achieving a fully healed intestinal mucosa may reduce this risk, contributing to lower morbidity and mortality in IBD patients.

SourceUniversity of Gothenburg·JournalClinical Gastroenterology and Hepatology·TypeObservational study·DateNov 1, 2023

B12 deficiency: a hidden trigger of inflammation?

A recent study found a compelling link between vitamin B12 deficiency and chronic inflammation, which can lead to various health problems. The research revealed an inverse relationship between vitamin B12 levels and inflammatory markers in humans and mice, suggesting that higher vitamin B12 levels may lower inflammatory markers.

SourceSociety of Chemical Industry·JournalJournal of the Science of Food and Agriculture·TypeObservational study·DateOct 17, 2023

Statins linked to lower risk of colorectal cancer in patients with ulcerative colitis

Researchers at Karolinska Institutet found that statin treatment was associated with a lower risk of developing and dying from colorectal cancer in patients with ulcerative colitis. After a follow-up period of 5.6 years, the study showed that 70 statin users had been diagnosed with colorectal cancer compared to 90 non-statin users.

SourceKarolinska Institutet·JournalEClinicalMedicine·TypeObservational study·DateSep 1, 2023

Network-based approaches open a new avenue to classify and treat rare diseases

Scientists at CeMM and Max Perutz Labs have reclassified approximately 200 rare immune system disorders using a network-based approach. The study reveals strong similarities between rare diseases and autoimmune conditions, enabling the prediction of treatment efficacy and personalized approaches for diagnosis and treatment.

Protective particles allow engineered probiotics to report gut disease

Researchers developed a platform that allows engineered biosensor bacteria to safely pass through the gastrointestinal tract in animal models. The platform enables real-time monitoring of gut health and can be used to diagnose and monitor various diseases, including inflammatory bowel disease. It has the potential to revolutionize pati...

SourceRice University·JournalBiomaterials·TypeExperimental study·DateAug 16, 2023

Study may explain why high-sugar diets can worsen IBD

A new study suggests that high-sugar diets can exacerbate inflammatory bowel disease (IBD) symptoms by disrupting the colon's lining renewal process. The research found that a high-sugar diet led to impaired cell division and altered metabolic pathways in mice, resulting in faster gut damage.

SourceUniversity of Pittsburgh·JournalCellular and Molecular Gastroenterology and Hepatology·TypeExperimental study·DateMay 22, 2023

NUS researchers report potential new treatment for leaky gut using milk-derived extracellular vesicles

Scientists discover that milk-derived extracellular vesicles can repair damaged gut barriers and prevent bacterial toxins from leaking into the bloodstream. The study shows promising results in treating leaky gut syndrome and related diseases such as inflammatory bowel disease and non-alcoholic fatty liver disease.

SourceNational University of Singapore, Yong Loo Lin School of Medicine·JournalScience Advances·TypeRandomized controlled/clinical trial·DateApr 13, 2023

Mass General researchers discover the role of intestinal fibrosis in inflammatory bowel disease

Researchers at Mass General Hospital have found that intestinal fibrosis plays a critical role in the progression of inflammatory bowel disease (IBD), affecting the growth and differentiation of intestinal stem cells. The study suggests targeting mechanosensing pathways may offer an attractive therapeutic strategy for IBD.

SourceMassachusetts General Hospital·JournalGastroenterology·TypeExperimental study·DateMar 8, 2023

Normal gastrointestinal biopsy not protective against later IBD, study finds

A new study found that individuals with a normal gastrointestinal biopsy still have a higher risk of developing inflammatory bowel disease (IBD) in the years following the biopsy. The study of over 450,000 individuals in Sweden showed that symptoms of IBD may start significantly before the disease shows up on biopsy.

SourcePLOS·JournalPLOS Medicine·TypeObservational study·DateFeb 23, 2023

Two previously unknown bacterial species identified from patients with inflammatory bowel disease

Researchers have isolated two new bacterial species from patients with inflammatory bowel disease (IBD), which break down the protective mucus layer of the gut. The bacteria, Allobaculum mucilyticum and Allobaculum fili, are highly efficient at degrading intestinal mucus, leading to potent immune responses.

SourceUniversity Medical Center Utrecht·JournalINTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY·TypeExperimental study·DateJan 12, 2023

Move over, mice: caterpillars could replace some mammals in the study of human disease

Scientists have found that caterpillars can be used as an alternative to rodent models for studying gut inflammation, a risk factor for colorectal cancer. The tobacco hornworm caterpillar has a high degree of similarity to the human gut structure and physiology, making it a promising model organism for future research.

SourceMemorial Sloan Kettering Cancer Center·JournalNature Communications·TypeExperimental study·DateJan 12, 2023

Probiotic 'backpacks' show promise for treating inflammatory bowel diseases

Researchers at the University of Wisconsin-Madison develop nanoparticles to neutralize molecules implicated in IBD, significantly improving treatment outcomes. The probiotic bacteria are equipped with nano-backpacks that target reactive oxygen species, reducing inflammation and promoting weight gain and colon length restoration.

SourceUniversity of Wisconsin-Madison·JournalScience Advances·TypeExperimental study·DateNov 11, 2022